Literature DB >> 28386720

Subcentimeter hypervascular nodules with typical imaging findings of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Outcomes of early treatment and watchful waiting.

Jung Han Woo1, Kyoung Doo Song2, Seong Hyun Kim1.   

Abstract

OBJECTIVES: To compare treatment outcomes of subcentimeter hypervascular nodules at high risk for developing into hepatocellular carcinomas (SHNHR) between early treatment and watchful waiting until progression to overt hepatocellular carcinoma (HCC) groups.
METHODS: SHNHRs were defined as subcentimeter hypervascular nodules with the usual imaging features of HCC on gadoxetic acid-enhanced magnetic resonance imaging (MRI). Among 63 patients with 74 SHNHRs, 27 (37 SHNHRs) received early treatment (treatment of < 1 cm nodules), and 36 (37 SHNHRs) underwent watchful waiting until progression to overt HCC. Risk factor analysis was performed for recurrence-free and local recurrence-free survival.
RESULTS: Among the 36 patients who adopted watchful waiting, 33 eventually underwent treatment because their SHNHRs progressed to overt HCC. For recurrence-free survival, significant risk factors included number of previous treatments (HR, 1.181; p < 0.001), tumour number (HR, 1.943; p = 0.009), and α-feto protein level (HR, 1.005; p = 0.037) in the multivariate analyses. Treatment strategy was not a significant risk factor for recurrence-free survival. For local recurrence-free survival from the date of treatment, only treatment modality (transarterial chemoembolization) (HR, 6.879; p = 0.002) was a significant risk factor.
CONCLUSION: Recurrence-free survival was not significantly different between early treatment and watchful waiting for SHNHRs. KEY POINTS: • Recurrence-free survival did not vary between the two treatment strategies. • Treatment modality was a significant factor for local recurrence-free survival. • Number of treatments, tumour number, and α-FP were risk factors for recurrence.

Entities:  

Keywords:  Early treatment; Hepatocellular carcinoma; Hypervascular nodule; Subcentimeter; Watchful waiting

Mesh:

Substances:

Year:  2017        PMID: 28386720     DOI: 10.1007/s00330-017-4818-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Major achievements in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

3.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

4.  Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging.

Authors:  Kyoung Doo Song; Seong Hyun Kim; Hyo Keun Lim; Sin-Ho Jung; Insuk Sohn; Hyung Sik Kim
Journal:  Eur Radiol       Date:  2015-03-04       Impact factor: 5.315

5.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

6.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

7.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

9.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

10.  Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.

Authors:  Elmar M Merkle; Christoph J Zech; Carlo Bartolozzi; Mustafa R Bashir; Ahmed Ba-Ssalamah; Alexander Huppertz; Jeong Min Lee; Jens Ricke; Michiie Sakamoto; Claude B Sirlin; Sheng-Long Ye; Mengsu Zeng
Journal:  Eur Radiol       Date:  2015-06-13       Impact factor: 5.315

View more
  3 in total

1.  Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection.

Authors:  Zhen Zhang; Jie Chen; Hanyu Jiang; Yi Wei; Xin Zhang; Likun Cao; Ting Duan; Zheng Ye; Shan Yao; Xuelin Pan; Bin Song
Journal:  Ann Transl Med       Date:  2020-07

Review 2.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

3.  Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?

Authors:  Xuqi Sun; Dandan Hu; Yaojun Zhang; Ning Lyu; Li Xu; Qifeng Chen; Jinfa Lai; Minshan Chen; Ming Zhao
Journal:  J Hepatocell Carcinoma       Date:  2020-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.